Alzchem Group AG Reports Continued Earnings Growth in Q1 2025

Alzchem Group AG, a specialty chemicals company, announced a 10% increase in Group EBITDA to EUR 27.4 million in the first quarter of 2025. Despite a 4% drop in sales, the EBITDA margin improved to 18.9%. The company attributes growth to its specialty chemicals segment, with sales rising 2% due to higher demand in human and animal nutrition, and custom manufacturing. However, the Basics & Intermediates segment saw a 14% decline in sales.

The firm's consolidated result increased by 20%, reaching EUR 14.6 million. Operating cash flow rose significantly due to customer payments linked to new nitroguanidine capacity expansion projects. Cash reserves grew to EUR 91.4 million.

Alzchem remains optimistic, forecasting a 5% sales growth in 2025. EBITDA is expected to increase by 7%, supported by the ongoing shift toward higher-margin products.